GlassScriptPhysician profile
Satheesh Kumar Kathula
NPI 1760432769
$297,090.69
in general payments reported to CMS, 2019-2025
60 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $9,156 · 2021: $36K · 2022: $58K · 2023: $49K · 2024: $58K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Consulting Fee: $39K · Travel and Lodging: $17K · Food and Beverage: $4,465 · Honoraria: $1,463 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,264.45 |
| Consulting Fee | $39,234.00 |
| Travel and Lodging | $16,996.31 |
| Food and Beverage | $4,465.32 |
| Honoraria | $1,463.00 |
| Education | $157.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $126,592.44 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Daiichi Sankyo INC. | $124,642.52 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $19,488.58 | 2021-2025 | Libtayo |
| American Regent | $14,872.60 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $6,881.90 | 2019-2023 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $475.90 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $348.21 | 2019-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $216.51 | 2019-2025 | |
| Astellas Pharma US INC | $216.34 | 2020-2025 | Padcev, Xospata |
| Amgen INC. | $205.54 | 2019-2023 | Kyprolis, Lumakras |
| Janssen Biotech, INC. | $200.27 | 2019-2023 | Darzalex, Imbruvica, Balversa |
| Seagen INC. | $196.08 | 2020-2023 | Adcetris |
| Gilead Sciences, INC. | $185.35 | 2022-2024 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $172.51 | 2019-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $165.42 | 2019-2023 | Venclexta |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satheesh Kathula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.